Switch theme
Sign up to access all valuation multiples
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
2018
300
LTM Revenue $43K
LTM EBITDA -$311M
-$180M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lyell Immunopharma has a last 12-month revenue of $43K and a last 12-month EBITDA of -$311M.
In the most recent fiscal year, Lyell Immunopharma achieved revenue of $0.1M and an EBITDA of -$201M.
Lyell Immunopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lyell Immunopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$227M | -$201M | XXX | XXX | XXX |
| EBITDA Margin | -174429% | -328923% | XXX | XXX | XXX |
| Net Profit | -$183M | -$235M | XXX | XXX | XXX |
| Net Margin | -140860% | -384643% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lyell Immunopharma's stock price is $0.
Lyell Immunopharma has current market cap of $131M, and EV of -$180M.
See Lyell Immunopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$180M | $131M | XXX | XXX | XXX | XXX | $-1.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lyell Immunopharma has market cap of $131M and EV of -$180M.
Lyell Immunopharma's trades at -4149.4x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.
Analysts estimate Lyell Immunopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lyell Immunopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$180M | XXX | XXX | XXX |
| EV/Revenue | -2955.7x | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLyell Immunopharma's NTM/LTM revenue growth is -100%
Lyell Immunopharma's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Lyell Immunopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lyell Immunopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lyell Immunopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -53% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -328923% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 85313% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 281316% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 361205% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lyell Immunopharma acquired XXX companies to date.
Last acquisition by Lyell Immunopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Lyell Immunopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lyell Immunopharma founded? | Lyell Immunopharma was founded in 2018. |
| Where is Lyell Immunopharma headquartered? | Lyell Immunopharma is headquartered in United States of America. |
| How many employees does Lyell Immunopharma have? | As of today, Lyell Immunopharma has 300 employees. |
| Who is the CEO of Lyell Immunopharma? | Lyell Immunopharma's CEO is Dr. Lynn Seely,M.D.. |
| Is Lyell Immunopharma publicy listed? | Yes, Lyell Immunopharma is a public company listed on NAS. |
| What is the stock symbol of Lyell Immunopharma? | Lyell Immunopharma trades under LYEL ticker. |
| When did Lyell Immunopharma go public? | Lyell Immunopharma went public in 2021. |
| Who are competitors of Lyell Immunopharma? | Similar companies to Lyell Immunopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lyell Immunopharma? | Lyell Immunopharma's current market cap is $131M |
| What is the current revenue of Lyell Immunopharma? | Lyell Immunopharma's last 12-month revenue is $43K. |
| What is the current EBITDA of Lyell Immunopharma? | Lyell Immunopharma's last 12-month EBITDA is -$311M. |
| What is the current EV/Revenue multiple of Lyell Immunopharma? | Current revenue multiple of Lyell Immunopharma is -4149.4x. |
| What is the current EV/EBITDA multiple of Lyell Immunopharma? | Current EBITDA multiple of Lyell Immunopharma is 0.6x. |
| What is the current revenue growth of Lyell Immunopharma? | Lyell Immunopharma revenue growth between 2023 and 2024 was -53%. |
| Is Lyell Immunopharma profitable? | Yes, Lyell Immunopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
